Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue?

Company Performance - Xeris Biopharma (XERS) has seen a stock increase of 19.7% over the past month, reaching a new 52-week high of $9.41 [1] - The stock has gained 172.6% since the beginning of the year, significantly outperforming the Zacks Medical sector's 0.7% gain and the Zacks Medical - Drugs industry's 8.1% return [1] Earnings and Revenue Expectations - Xeris Biopharma has a strong record of positive earnings surprises, beating the Zacks Consensus Estimate in the last four quarters [2] - For the current fiscal year, the company is expected to post earnings of -$0.01 per share on revenues of $287.18 million, reflecting a 96.97% change in EPS and a 41.42% change in revenues [3] - For the next fiscal year, earnings are projected to be $0.31 per share on revenues of $349.68 million, indicating a year-over-year change of 3275% in EPS and 21.76% in revenues [3] Valuation Metrics - Xeris Biopharma has a Value Score of D, while its Growth and Momentum Scores are both A, resulting in a combined VGM Score of A [6] - The stock currently holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates, suggesting potential for further gains [7] Industry Comparison - The Medical - Drugs industry is positioned in the top 26% of all industries, indicating favorable conditions for both Xeris Biopharma and its peer, Ironwood Pharmaceuticals [10] - Ironwood Pharmaceuticals has a Zacks Rank of 1 (Strong Buy) and has shown strong earnings performance, beating consensus estimates by 800% [9]